• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Big Cypress Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    10/21/21 7:30:47 AM ET
    $BCYP
    Finance
    Get the next $BCYP alert in real time by email
    0001833214 false 0001833214 2021-10-20 2021-10-20 0001833214 BCYP:UnitsEachConsistingOfOneShareOfCommonStockAndOneHalfOfOneRedeemableWarrantMember 2021-10-20 2021-10-20 0001833214 BCYP:CommonStockParValue0.0001PerShareMember 2021-10-20 2021-10-20 0001833214 BCYP:RedeemableWarrantsEachWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2021-10-20 2021-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

     

    FORM 8-K

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): October 20, 2021

     

    Big Cypress Acquisition Corp.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-39871   85-3899721
    (State or Other Jurisdiction   (Commission   (IRS Employer
    of Incorporation)   File Number)   Identification No.)

     

    300 W. 41st Street, Suite 202

    Miami Beach, FL 33140
    (Address of Principal Executive Offices) (Zip Code)

     

    (305) 204-3338

    (Registrant’s Telephone Number, Including Area Code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of Common Stock and one half of one redeemable warrant   BCYPU   The Nasdaq Stock Market LLC
    Common Stock, par value $0.0001 per share   BCYP   The Nasdaq Stock Market LLC
    Redeemable warrants, each warrant exercisable for one share of Common Stock at an exercise price of $11.50   BCYPW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On October 20, 2021, Big Cypress Acquisition Corp. (“Big Cypress” or the “Company”) held a special meeting (the “Special Meeting”) of the stockholders of the Company virtually via live webcast at https://www.cstproxy.com/bigcypressaccorp/2021, at which holders of 11,825,012 shares of common stock were present in person or by proxy, representing 79.94% of the voting power of the shares of the Company’s common stock as of September 17, 2021, the record date for the Special Meeting (stockholders of record as of the close of business on the record date are referred to herein as “Stockholders”). Each of the proposals listed below is described in more detail in the Company’s definitive proxy statement/prospectus filed with the United States Securities and Exchange Commission on September 24, 2021 (the “Proxy Statement”). A summary of the voting results at the Special Meeting for each of the proposals is set forth below:

     

    Proposal No. 1: The Stockholders approved and adopted Agreement and Plan of Merger, dated as of June 21, 2021, as amended August 12, 2021 (the “Merger Agreement”), by and among Big Cypress, Big Cypress Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Big Cypress, and SAB Biotherapeutics, Inc., a Delaware corporation (“SAB Biotherapeutics”), and the transactions contemplated thereby, which will ultimately result in SAB Biotherapeutics becoming a wholly-owned direct subsidiary of the Company. The voting results for this proposal were as follows:

     

    For   Against   Abstain   Broker Non-Votes
    11,622,247   202,765   0   N/A

     

    Proposal No. 2: The Stockholders approved amendments to the Company’s Amended and Restated Certificate of Incorporation, which are reflected in the proposed Second Amended and Restated Certificate of Incorporation of Big Cypress (the “Proposed Charter”) (which, if approved, would take effect upon consummation of the Business Combination) the full text of which is attached to the Proxy Statement as Annex C. The voting results for this proposal were as follows: 

     

    For   Against   Abstain   Broker Non-Votes
    11,420,247   202,765   202,000   N/A

     

    Proposal No. 3: The Stockholders approved a proposal to approve, for purposes of complying with the applicable provisions of Nasdaq Rules 5635(a), (b) and (d), the issuance of more than 20% of the issued and outstanding shares of the Company’s common stock in connection with the transactions contemplated by the Business Combination Agreement, and the potential change of control in connection with the Business Combination. The voting results for this proposal were as follows: 

     

    For   Against   Abstain   Broker Non-Votes
    11,420,247   202,765   202,000   N/A

     

     

     

     

    Proposal No. 4: The Stockholders approved a proposal to approve and adopt the 2021 Incentive Plan, including the authorization of the initial share reserve thereunder. The voting results for this proposal were as follows: 

     

    For   Against   Abstain   Broker Non-Votes
    11,237,288   385,724   202,000   N/A

     

    Proposal No. 5: The Stockholders approved a proposal to approve and adopt the Employee Stock Purchase Plan, including the authorization of the initial share reserve thereunder. The voting results for this proposal were as follows: 

     

    For   Against   Abstain   Broker Non-Votes
    11,417,230   204,767   203,015   N/A

     

    Proposal No. 6: The Stockholders approved the election of the seven directors named in the Proxy Statement to serve, effective upon the closing of the Business Combination, staggered terms on the Board until the 2021, 2022 and 2023 annual meetings of stockholders, respectively, and until their respective successors are duly elected and qualified.

     

    The voting results with respect to the election of Samuel J. Reich were as follows:

     

    For   Withhold     Broker Non-Votes
    11,619,707   205,305     N/A

     

    The voting results with respect to the election of Jeffrey G. Spragens were as follows:

     

    For   Withhold     Broker Non-Votes
    11,620,232   204,780     N/A

     

    The voting results with respect to the election of Christine Hamilton, MBA were as follows:

     

    For   Withhold     Broker Non-Votes
    11,620,730   204,282     N/A

     

    The voting results with respect to the election of William Polvino, MD were as follows:

     

    For   Withhold     Broker Non-Votes
    11,620,232   204,780     N/A

     

    The voting results with respect to the election of Mervyn Turner, PhD were as follows:

     

    For   Withhold     Broker Non-Votes
    11,620,232   204,780     N/A

     

    The voting results with respect to the election of David Link, MBA were as follows:

     

    For   Withhold     Broker Non-Votes
    11,620,232   204,780     N/A

     

    The voting results with respect to the election of Eddie J. Sullivan, PhD were as follows:

     

    For   Withhold     Broker Non-Votes
    11,620,207   204,805     N/A

     

    Proposal No. 7: The Stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes to approve the Business Combination Proposal, the Charter Amendment Proposal, the Nasdaq Proposal, the Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal or the Director Election Proposal. The voting results for this proposal were as follows:

     

    For   Against   Abstain   Broker Non-Votes
    10,984,899   840,113   0   N/A

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BIG CYPRESS ACQUISITION CORP.
         
      By: /s/ Samuel J. Reich
      Name: Samuel J. Reich
      Title: Chief Executive Officer & Chief Financial Officer

     

    Dated: October 21, 2021

     

     

     

    Get the next $BCYP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCYP

    DatePrice TargetRatingAnalyst
    10/4/2021$18.00Outperform
    Northland Capital Markets
    10/1/2021$16.50Buy
    Ladenburg Thalmann
    More analyst ratings

    $BCYP
    Leadership Updates

    Live Leadership Updates

    See more
    • SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

      SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t

      9/28/21 7:00:00 AM ET
      $BCYP
      Finance

    $BCYP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Northland Capital Markets initiated coverage on Big Cypress Acquisition with a new price target

      Northland Capital Markets initiated coverage of Big Cypress Acquisition with a rating of Outperform and set a new price target of $18.00

      10/4/21 10:23:14 AM ET
      $BCYP
      Finance
    • Ladenburg Thalmann initiated coverage on Big Cypress Acquisition with a new price target

      Ladenburg Thalmann initiated coverage of Big Cypress Acquisition with a rating of Buy and set a new price target of $16.50

      10/1/21 7:00:04 AM ET
      $BCYP
      Finance

    $BCYP
    SEC Filings

    See more
    • Big Cypress Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

      8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

      10/28/21 5:16:44 PM ET
      $BCYP
      Finance
    • SEC Form 25-NSE filed by Big Cypress Acquisition Corp.

      25-NSE - Big Cypress Acquisition Corp. (0001833214) (Subject)

      10/22/21 4:18:33 PM ET
      $BCYP
      Finance
    • Big Cypress Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)

      10/21/21 7:30:47 AM ET
      $BCYP
      Finance

    $BCYP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 7:38:40 PM ET
      $BCYP
      Finance
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 4:57:43 PM ET
      $BCYP
      Finance
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 4:55:01 PM ET
      $BCYP
      Finance

    $BCYP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Carillo Carlos N

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:53:55 PM ET
      $BCYP
      Finance
    • SEC Form 4 filed by Erickson Bruce Kipp

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:53:05 PM ET
      $BCYP
      Finance
    • SEC Form 4 filed by Wu Hua

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:52:27 PM ET
      $BCYP
      Finance

    $BCYP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

      Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (NASDAQ:BCYP) ("Big Cypress"), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical

      10/25/21 7:39:57 AM ET
      $BCYP
      Finance
    • Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

      MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Special Meeting of stockholders held on October 20, 2021 (the "Special Meeting"). Approximately 98.3% of t

      10/21/21 7:00:00 AM ET
      $BCYP
      Finance
    • SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

      SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs. The event will feature SAB management and key opinion leaders, including: Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins B

      10/6/21 7:00:00 AM ET
      $BCYP
      Finance